ENSC Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
1.2M
+21.2%
961.0K
-48.9%
1.9M
+281.7%
493.1K
-64.0%
1.4M
Cost of Revenue
0
0
0
0
0
Gross Profit
1.2M
+21.2%
961.0K
-48.9%
1.9M
+281.7%
493.1K
-64.0%
1.4M
Operating Expenses
3.7M
-17.3%
4.5M
-3.0%
4.7M
+10.2%
4.2M
+35.6%
3.1M
R&D
2.5M
-26.1%
3.3M
-7.4%
3.6M
+22.3%
3.0M
+53.6%
1.9M
SG&A
1.3M
+7.9%
1.2M
+11.9%
1.1M
-17.8%
1.3M
+6.7%
1.2M
Operating Income
-2576389
+27.7%
-3562230
-28.1%
-2781825
+25.6%
-3741095
-113.7%
-1750515
EBITDA
-2569856
+27.7%
-3555697
-28.1%
-2775292
+25.8%
-3741095
-113.7%
-1750515
Net Income
-2570875
+27.7%
-3556415
-28.5%
-2767969
+25.8%
-3729128
-115.1%
-1733517
EPS (Basic)
$-0.20
+61.5%
$-0.52
+29.7%
$-0.74
+42.6%
$-1.29
-63.3%
$-0.79
EPS (Diluted)
$-0.20
+61.5%
$-0.52
+29.7%
$-0.74
+42.6%
$-1.29
-63.3%
$-0.79
Shares (Diluted)
13.0M
+90.6%
6.8M
+82.9%
3.7M
+29.6%
2.9M
+31.0%
2.2M
Ensysce Biosciences (ENSC) โ€” Financials